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Abstract
In CF patients with mild or moderate lung disease, the most sensitive spirometric measure of response to dornase alfa is peripheral
airﬂow. Cross-over studies in patients, already stabilised on dornase alfa, indicate that peripheral airﬂow shows greater improvement when
it is administered 30 minutes before airway clearance therapy (ACT) rather than shortly after ACT. These results are consistent with the
hypothesis that the major role of dornase alfa is to facilitate expectoration of sputum during ACT. When ACT is performed in the morning,
efﬁcacy and safety are similar when dornase alfa is inhaled before bedtime or upon awakening. Most patients may therefore choose the most
convenient time of day to inhale dornase alfa provided that they wait at least 30 minutes before performing ACT. Further research is necessary
to establish the optimum regimen in patients with more advanced lung disease.
© 2009 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.
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1. Introduction
Airway clearance is central to the treatment of cystic ﬁbro-
sis (CF) and is implemented using airway clearance therapy
(ACT) and/or exercise together with nebulised dornase alfa.
However, the timing of dornase alfa inhalation with respect
to ACT that achieves the optimal result has only recently
been studied. In clinical practice, the same proportion of
patients is reported to inhale it before versus after ACT [1].
There are theoretical grounds to suppose that either regimen
might be more beneﬁcial: on the one hand dornase alfa
may help patients expectorate sputum more efﬁciently during
subsequent ACT; alternatively dornase alfa inhaled after ACT
may be deposited more efﬁciently into the peripheral airways
and thereby promote expectoration of sputum that was not
expelled during prior ACT. The purpose of this presentation
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is to summarise current knowledge on the optimal timing of
dornase alfa with respect to ACT.
Dornase alfa reduces the viscoelasticity of CF sputum by
cleaving long-chain DNA, a highly viscous macromolecule
released by neutrophils during inﬂammation of the CF airway
[2]. In vitro, the maximal effects of dornase alfa on CF
sputum viscosity and pourability require about 30 minutes
[3]. Maintenance therapy with dornase alfa has been shown
to improve pulmonary function [4–6] and to reduce the risk
of acute pulmonary exacerbations [5,6] as well as antibiotic
use and hospitalisation rates [5]. In patients with early lung
disease its largest and most sustained effect is on peripheral
airﬂow [6].
A previous study in 52 children with mild-to-moderate
CF lung disease who were not on dornase alfa maintenance
therapy did not detect any difference in lung function when
dornase alfa was initiated 30 minutes before versus 30 minutes
after ACT for 2 weeks. However, a post-hoc subanalysis
suggested that dornase alfa may be more effective on forced
expiratory volume in 1 second (FEV1) in children chronically
colonised with Ps. aeruginosa when administered after ACT
[7]. The objective of the current research was to determine,
in patients already stabilised on dornase alfa treatment,
(A) the regimen of timing of dornase alfa with respect
to ACT that yields the greatest improvement in peripheral
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ﬂow; and (B) whether it is safe and effective to permit a
night’s sleep to intervene between dornase alfa inhalation and
ACT.
2. Methods
A: Dornase alfa before versus after ACT
CF patients over 5 years of age were eligible for this study
if they were able to perform reproducible spirometry, per-
formed daily ACT, and had been on dornase alfa therapy and
clinically stable for ≥1 month [8]. Patients were randomised
to inhale either placebo 30 minutes before and dornase alfa
immediately after ACT, or dornase alfa 30 minutes before and
placebo immediately after ACT, in a double-blind, double-
dummy fashion. After 3 weeks of treatment they were crossed
over to the alternative regimen. All patients continued to
perform ACT in the same way as before the intervention and
spirometry was measured at home by the investigator. Primary
endpoints were peripheral ﬂow as assessed by expiratory ﬂow
at 25% of vital capacity (FEF75) after 2 and 3 weeks of
each regimen. Secondary endpoints were other spirometric
parameters, as well as sputum amount and viscosity and
cough frequency, as recorded in a patient diary during the
third week of each treatment regimen.
B: Dornase alfa before versus after sleep
Design and inclusion criteria were similar to the previous
study [9]. Patients were randomised to inhale either dornase
alfa before bedtime and placebo upon awakening, or placebo
before bedtime and dornase alfa upon awakening. In both
arms of the study, ACT was performed 30 minutes after the
morning nebulisation. After 2 weeks of treatment patients
were crossed over to the alternative regimen. The primary
endpoint was FEF75 after 2 weeks of treatment. Secondary
endpoints were other pulmonary function tests, cough fre-
quency as assessed by an audio recording of overnight cough
sounds and a day- and night-time cough symptom score,
oxygen saturation as measured by overnight pulse oximetry,
and signs and symptoms as recorded in a patient diary.
3. Results
A: Dornase alfa before versus after ACT
Twenty-ﬁve patients were enrolled and 24 completed the
study. Mean age was 12 years and, while FEV1 and FVC
were within the normal range at baseline, peripheral ﬂows
as assessed by FEF75 and forced expiratory ﬂow at 25–75%
of vital capacity (FEF25–75) were substantially reduced. The
treatment groups were well matched (Table 1). The principal
ACT techniques used were PEP mask (75%) and the ﬂutter
device (13%).
The primary endpoint (FEF75) was signiﬁcantly higher, by
about 6% predicted, after 3 weeks’ treatment when dornase
alfa was administered 30 minutes before versus immediately
Table 1
Characteristics of the population in the study of dornase alfa before versus
after ACT at baseline for groups 1 and 2 (numbers of patients, or mean with
SD) [8]. Reproduced with permission
Group 1 Group 2
N 11 13 NS
Sex (male/female) 6/5 7/6 NS
Age (years) 11 (3) 12 (4) NS
FVC (% predicted) 93 (14) 93 (11) NS
FEV1 (% predicted) 88 (16) 88 (11) NS
FEF75 (% predicted) 56 (27) 57 (25) NS
Use of TOBI (n) 7 6 NS
Fig. 1. FEF75 % predicted when dornase alfa was inhaled 30 minutes after
versus immediately before ACT: results after 3 weeks’ treatment. Lines
connect individual data points. Bars represent mean values [8]. Reprinted
with permission of John Wiley & Sons, Inc..
Table 2
Mean lung function (% predicted) with range after two and three weeks of
dornase alfa treatment before or after ACT [8]. Reproduced with permission
of John Wiley & Sons, Inc.
FVC % FEV1 % FEF75 %
After 2 weeks
RhDNase after ACT 94.8 (76–131) 89.5 (68–116) 54.2 (18–104)
RhDNase before ACT 92.5 (72–123) 87.1 (57–107) 54.1 (8–103)
p-value 0.12 0.18 0.98
After 3 weeks
RhDNase after ACT 94.1 (75–131) 88.3 (67–105) 52.5 (11–93)
RhDNase before ACT 93.3 (75–127) 89.4 (66–113) 58.3 (17–105)
p-value 0.65 0.58 0.01 ‡
‡ p < 0.05.
after ACT (Fig. 1, Table 2). Neither the difference in FEF75
after 2 weeks’ treatment nor any of the secondary endpoints
was signiﬁcantly different between the groups.
B: Dornase alfa before versus after sleep
Again, 25 patients were enrolled and 24 completed the
study. Mean age was 13 years and, while FVC was normal,
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Table 3
Characteristics of the population in the study of dornase alfa before versus
after sleep at baseline for groups I and II (numbers of patients, or mean with
SD) [9]. Reproduced with permission
Group I Group II
N 11 13 NS
Sex (male/female) 3/8 5/8 NS
Age (years) 12.5 (4.5) 13.5 (3.4) NS
FVC (% predicted) 81 (9) 82 (22) NS
FEV1 (% predicted) 74 (12) 76 (27) NS
FEF75 (% predicted) 49 (32) 49 (34) NS
Use of TOBI (n) 3 5 NS
mean FEV1 was slightly and FEF75 considerably below
normal limits at baseline. The treatment groups were well
matched (Table 3). There was no signiﬁcant difference
between groups in any of the efﬁcacy or safety parameters
after either 1 or 2 weeks.
4. Discussion
In patients with well preserved lung function, the most
prominent response to dornase alfa is in the peripheral
airways [6]. Therefore spirometric measures of peripheral
airﬂow such as FEF75 are more sensitive endpoints than FEV1
for comparing dornase alfa regimens with respect to ACT in
this population.
Although it is accepted that maximal spirometric responses
to dornase alfa are achieved after 2 weeks of treatment,
long-term studies suggest that they reach a peak at 1–2 weeks
[5] or 4–12 weeks [6] of treatment but shorter time intervals
have not been studied. The optimum duration of therapy
for determining maximum short-term responses is therefore
not clear. The result of the study of Fitzgerald et al. [7] is
consistent with our results in that no signiﬁcant difference was
detected after two weeks of treatment. While 2 weeks may
be too short to detect the maximal response to treatment, an
alternative explanation for their result is that variability among
patient responses to the initiation of drug treatment may have
been greater than the variability between dornase alfa regi-
mens, making it difﬁcult to detect small differences between
regimens. Furthermore, the extent of inhaled antibiotic use
in their subpopulations with and without chronic colonisation
by Ps. aeruginosa was not described. If, as suggested [10],
dornase alfa improves penetration of inhaled antibiotics into
sputum and bioﬁlms, then uncontrolled differences in the use
of such antibiotics may have confounded the trial results.
A more recent randomised crossover study has reported
that FEF75 increased by 20% and quality of life was sig-
niﬁcantly improved when patients’ regimens were modiﬁed
for 2 weeks to allow dornase alfa to dwell in the airways
for >6 hours as opposed to <6 hours before their usual
ACT session [11]. The actual median dwell times were 15
minutes versus 11.1 hours. Unfortunately, the shorter dwell
time of 15 minutes is insufﬁcient to permit the full effect
of dornase alfa on sputum in vitro [3] but the long dwell
time is probably responsible for the great difference in FEF75
between the two regimens. Our study indicates that a dwell
time of 30 minutes before ACT is already more effective
than administering dornase alfa immediately after ACT, and
suggests that 30 minutes may be the minimum dwell time for
optimal efﬁcacy. In other respects, the results of Wilson et al.
are consistent with our own.
Our study of dornase alfa inhaled before versus after
sleep, with ACT performed in the morning, is reassuring.
There was no sign of decreased tolerance to dornase alfa
during sleep, despite the facts that, during sleep, mucociliary
clearance [12,13] and the cough reﬂex [14] are depressed and
a quiet tidal volume pattern of breathing supervenes [15,16].
Speciﬁcally, oxygen saturation was not reduced during the
night and there was no increased cough. Therefore, in patients
with mild to moderate CF lung disease who perform ACT
in the morning, our data indicate that it is equally safe and
effective to administer dornase alfa before sleep and upon
awakening. This implies that the actual timing of dornase alfa
administration during the day is not critical, and that patients
may therefore choose the most convenient time to inhale it.
The endpoint of our study on timing with respect to
sleep was assessed after 2 weeks’ treatment with dornase
alfa, while a signiﬁcant difference in peripheral ﬂow was
detected after 3 but not 2 weeks’ treatment in our study with
respect to ACT. Nevertheless, Wilson [11] found a signiﬁcant
difference between short and long dwell times already after 2
weeks. While further research may explain this discrepancy,
we believe that future studies should extend the duration of
therapy to at least 3 weeks.
In more severe lung disease, peripheral ﬂows may well
have deteriorated irreversibly and FEV1 may be a more
appropriate endpoint than FEF75 for discriminating between
drug regimens [17]. The optimal timing of dornase alfa with
respect to ACT and the safety of an overnight dwell need
further research in such patients.
Finally, delivery to the lungs of any inhaled medication
is generally inefﬁcient and depends on the aerosol device
employed [18]. New devices that generate smaller particles
with a limited size range may be more effective in delivering
aerosol to the peripheral lung, and may have an important
impact on the effectiveness of dornase alfa [18].
5. Conclusions
In mild or moderate CF lung disease, it is reasonable to
conclude that it is more effective to administer dornase alfa
30 minutes before ACT than shortly after ACT. In addition
we showed that inhalation of dornase alfa immediately before
sleep is as safe and effective as its administration in the
morning. This is consistent with the hypothesis that the major
role of dornase alfa is to facilitate expectoration of sputum
during ACT. Patients may choose the most convenient time
of day for its inhalation. The optimal regimen for patients
with advanced lung disease requires further study. New
inhalation devices may enhance the efﬁcacy of dornase alfa
by improving its deposition in the peripheral lung.
L. van der Giessen / Journal of Cystic Fibrosis Volume 8 Suppl 1 (2009) S6–S9 S9
Acknowledgements
The ﬁrst draft of this manuscript, based on the author’s
slides and a recording of the presentation, was prepared by
Sheila McKenzie, a native English writer whose assistance
was funded by Roche.
Conﬂict of interest statement
L. van der Giessen has received an unrestricted research
grant and honoraria and travel expenses for lectures from
Roche Netherlands.
References
[1] Borsje P, de Jongste JC, Mouton JW, Tiddens HA. Aerosol ther-
apy in cystic ﬁbrosis: a survey of 54 CF centers. Pediatr Pulmonol
2000;30(5):368–76.
[2] Henke MO, Renner A, Huber RM, Seeds MC, Rubin BK. MUC5AC
and MUC5B mucins are decreased in cystic ﬁbrosis airway secretions.
Am J Respir Cell Mol Biol 2004;31: 86–91.
[3] Shak S, Capon DJ, Hellmiss R, Marsters SA, Baker CL. Recombinant
human DNase I reduces the viscosity of cystic ﬁbrosis sputum. Proc
Natl Acad Sci U S A 1990;87:9188–92.
[4] Jones AP, Wallis CE. Recombinant human deoxyribonuclease for cystic
ﬁbrosis. Cochrane Database Syst Rev 2003;(3):CD001127.
[5] Fuchs HJ, Borowitz DS, Christiansen DH et al. Effect of aerosolized
recombinant human DNase on exacerbations of respiratory symptoms
and on pulmonary function in patients with cystic ﬁbrosis. N Engl J
Med 1994;331:637–42.
[6] Quan J, Tiddens HAWM, Sy JP et al. A two-year randomized, placebo-
controlled trial of dornase alfa in young patients with cystic ﬁbrosis
with mild lung function abnormalities. J Pediatr 2001;139:813–20.
[7] Fitzgerald DA, Hilton J, Jepson B, Smith L. A crossover, randomized,
controlled trial of dornase alfa before versus after physiotherapy in
cystic ﬁbrosis. Pediatrics 2005;116:549–54.
[8] Van der Giessen LJ, de Jongste JC, Gosselink R, Hop WC, Tid-
dens HA. RhDNase before airway clearance therapy improves airway
patency in children with CF. Pediatr Pulmonol 2007;42:624–30
[9] Van der Giessen LJ, Gosselink R, Hop WC, Tiddens HA. Recombinant
human DNase nebulisation in children with cystic ﬁbrosis: before
bedtime or after waking up? Eur Respir J 2007;30:763–8.
[10] Doering G, Hoiby N. Early intervention and prevention of lung disease
in cystic ﬁbrosis: a European consensus. J Cyst Fibrosis 2004;3:67–91.
[11] Wilson CJ, Robbins LJ, Murphy JM, Chang AB. Is a longer time
interval between recombinant human deoxyribonuclease (dornase alfa)
and chest physiotherapy better? A multi-center, randomized crossover
trial. Pediatr Pulmonol 2007;42:1110–6.
[12] Bateman JRM, Pavia D, Clarke SW. The retention of lung secretions
during the night in normal subjects. Clin Sci Mol Med 1978;55:523–7.
[13] Hasani A, Agnew JE, Pavia D, Vora H, Clarke SW. Effect of oral
bronchodilators on lung mucociliary clearance during sleep in patients
with asthma. Thorax 1993;48:287–9.
[14] Widdicombe J, Fontana G. Cough: what’s in a name? Eur Respir J
2006;28:10–5.
[15] Tepper RS, Skatrud JB, Dempsey JA. Ventilation and oxygenation
changes during sleep in cystic ﬁbrosis. Chest 1983;84:388–93.
[16] George CF, West P, Kryger MH. Oxygenation and breathing pattern
during phasic and tonic REM in patients with chronic obstructive
pulmonary disease. Sleep 1987;10:234–43.
[17] Tiddens HA. Detecting early structural lung damage in cystic ﬁbrosis.
Pediatr Pulmonol 2002;34:228–31.
[18] Bakker EM, Tiddens HA. Pharmacology, clinical efﬁcacy and safety
of recombinant human DNase in cystic ﬁbrosis. Expert Rev Resp Med
2007;1:317–29.
